ClinicalTrials.gg
RecruitingNCT06265285Updated Oct 2, 2026

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

A Phase 2 interventional study of Home Health Encounter and Nivolumab in Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma and Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Primary conditionEsophageal Squamous Cell CarcinomaRegistry: Esophageal NeoplasmsReclassifiedWhy we changed it
Registry
Esophageal Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Esophageal Squamous Cell Carcinoma
Why
  1. The study's listed conditions name Esophageal Squamous Cell Carcinoma, a narrower term within Esophageal Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Mayo Clinic · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 6 months later.
Updated Oct 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing nivolumab in Esophageal Squamous Cell Carcinoma — 2 open to participants now, 3 under way, none of them phase 3. Nivolumab · Esophageal Squamous Cell Carcinoma.

Planned enrollment
4th of 10
50 · median 46
Started
2024
the only one that year
Phase 2
7 of 10
2 open now
Registered
9th of 10
by date
Lead sponsor
1 of 10
Mayo Clinic

Among the 10 studies testing nivolumab in Esophageal Squamous Cell Carcinoma, this one is the 4th largest by planned enrollment, is the only one that started in 2024, is one of 7 in phase 2, and was the 9th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

2 of the 10 studies testing nivolumab in Esophageal Squamous Cell Carcinoma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing nivolumab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most drug-related cancer care is conducted in clinic type centers or hospitals which may isolate patients from family, friends and familiar surroundings for many hours per day. This separation adds to the physical, emotional, social, and financial burden for patients and their families. Traveling to and from medical facilities costs time, money, and effort and can be a disadvantage to patients living in rural areas, those with low incomes or poor access to transport. Studies have shown that cancer patients often feel more comfortable and secure being cared for in their own home environments. SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve the quality of life in cancer patients.

Read the detailed description

PRIMARY OBJECTIVE:

I. Determine the change in patient-reported rating of Cancer Connected Access and Remote Expertise (CARE) after 8 weeks in clinic compared to the same rating after 8 weeks at home.

SECONDARY OBJECTIVES:

I. Evaluate patient preference for location of cancer treatment administration, in the clinic or in the home.

II. Longitudinally assess patient-reported function and global health/quality of life.

III. Longitudinally assess patient-reported symptoms. IV. Assess the safety of cancer directed therapy when administered at home by a home health provider with remote patient monitoring and command center support.

V. Describe emergency room visits and hospitalizations over the course of the study.

VI. Describe overall survival (data collected out to 1 year).

TERTIARY OBJECTIVE:

I. Assess the cost outcomes related to patient treatment in the clinic or in the home.

OUTLINE:

Patients receive nivolumab SC on day 1 of each cycle. Cycles repeat every 28 days in clinic for 2 cycles, then at home by a home health nursing provider (HHNP) for 4 cycles, followed by either in-clinic or at-home administration for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients receive in-home visits by a home health nurse, undergo remote patient monitoring including vital sign measurements and condition-specific symptom assessments throughout the study.

After completion of study treatment, patients are followed up at days 30 and 100, then every 3 months for up to 1 year.

03

Conditions studied

  • Advanced Esophageal Squamous Cell Carcinoma
  • Advanced Renal Cell Carcinoma
  • Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8
  • Clinical Stage IIB Cutaneous Melanoma AJCC v8
  • Clinical Stage IIC Cutaneous Melanoma AJCC v8
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
  • Esophageal Carcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Hepatocellular Carcinoma
  • Locally Advanced Urothelial Carcinoma
  • Lung Non-Small Cell Carcinoma
  • Malignant Solid Neoplasm
  • Metastatic Colorectal Carcinoma
  • Metastatic Cutaneous Melanoma
  • Metastatic Esophageal Squamous Cell Carcinoma
  • Metastatic Head and Neck Squamous Cell Carcinoma
  • Metastatic Urothelial Carcinoma
  • Recurrent Esophageal Squamous Cell Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Renal Cell Carcinoma
  • Stage III Renal Cell Cancer AJCC v8
  • Stage IV Colorectal Cancer AJCC v8
  • Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
  • Stage IV Renal Cell Cancer AJCC v8
  • Unresectable Cutaneous Melanoma
  • Unresectable Esophageal Squamous Cell Carcinoma
  • Urothelial Carcinoma
  • Unresectable Urothelial Carcinoma
04

In context

Esophageal Squamous Cell Carcinoma Reclassified

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

This study's planned enrollment of 50 is below the median of 64 across 564 interventional studies indexed under Esophageal Squamous Cell Carcinoma.

Browse Esophageal Squamous Cell Carcinoma studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.

Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.

Compared within Esophageal Squamous Cell Carcinoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Esophageal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • confirmed for which treatment with intravenous nivolumab is currently Food and Drug Administration (FDA) approved and who are recommended to initiate a new treatment regimen with single agent intravenous (IV) nivolumab by their treating oncologist for any of the indications outlined below and who are willing to switch to subcutaneous nivolumab. Additionally, patients who are currently receiving single-agent IV nivolumab are eligible, provided they transition to subcutaneous nivolumab on-study, with their first subcutaneous (subQ) dose administered on cycle 1, day 1 of the study.

    • Single agent nivolumab administered in the setting for one of the following indications:

      • Completely resected stage IIB/C, III or IV melanoma
      • Urothelial carcinoma status post radical resection and have a high risk of recurrence
      • Completely resected esophageal or gastroesophageal junction carcinoma with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT)
    • Single agent nivolumab for advanced/ cancer for one or more of the following indications:

      • Renal cell carcinoma (RCC) patients who have received prior anti-angiogenic therapy
      • Non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy (Note: patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving nivolumab)
      • Unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy
      • Unresectable or metastatic cutaneous melanoma
      • Locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
      • Unresectable or metastatic urothelial carcinoma, as treatment in combination with cisplatin and gemcitabine.

        • Subcutaneous nivolumab to be initiated as monotherapy following six cycles of cisplatin + gemcitabine
      • Recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy
      • Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan
    • Patients transitioning to maintenance nivolumab and who are willing to switch to subcutaneous nivolumab after completion of Ipilimumab and nivolumab combination therapy for one or more of the indications listed below (Note: patients who discontinue ipilimumab for immune-related toxicities, but are deemed to be eligible to continue on single agent nivolumab maintenance by their treating oncologist are eligible):

      • First-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC)
      • Unresectable or metastatic cutaneous melanoma
      • Hepatocellular carcinoma (HCC) previously treated with sorafenib
      • Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan
    • Single agent nivolumab administered in the adjuvant setting following neoadjuvant nivolumab with platinum doublet chemotherapy for patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements
  • Patients have recovered from the effects of any previous chemotherapy, immunotherapy, other prior systemic anticancer therapy, radiotherapy, and/or surgery (i.e., residual toxicity no worse than grade 1 [grade 2 treatment-associated peripheral neuropathy, grade 2 fatigue and/or any grade of alopecia are acceptable assuming all other inclusion criteria are met]) before registration
  • (ECOG) performance status (PS) 0 or 1
  • (AST) values ≤ 3 × the (ULN). For patients with documented baseline liver metastasis, the following limits will apply: 5 × ULN for transaminase
  • Alanine transaminase (ALT) values ≤ 3 x the upper limit of normal (ULN). For patients with documented baseline liver metastasis, the following limits will apply: 5 x ULN for transaminase
  • Serum total values of ≤ 1.5 x ULN ( ≤ 2 x ULN for patients with known Gilbert's syndrome). For patients with documented baseline liver metastasis, the following limits will apply: 2 x ULN for bilirubin
  • (ANC) of ≥ 1500/μL
  • count of ≥ 100,000/μL
  • of ≥ 9 g/dL (patients may be transfused to this level, if necessary, but transfusion must occur > 1 week prior to registration)
  • Serum creatinine ≤ 2.0 x the ULN for the reference laboratory or a calculated of ≥ 30 mL/min by the Cockcroft-Gault Equation measured ≤ 7 days prior to registration
  • Patients are residing ≤ 35 miles of clinic (hub) or within the area serviced by supplier and paramedic network
  • Residence has Wi-Fi to enable a reliable connection with the remote command center
  • Patients have signed Form (ICF)
  • Patients are willing and able to comply with the study protocol in the investigator's judgment
  • Patients are able and willing to complete study questionnaire(s) by themselves or with assistance
  • Women of (WOCBP) must:

    • Have a negative pregnancy test (serum or urine) ≤ 3 days before the first dose of study drug
    • Be agreeable to use a method that is highly effective during the intervention period and for at least 5 months after the last dose and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction for the same time period

Exclusion criteria

Exclusion Criteria:

  • Patients receiving any other or standard of care agent which would be considered as a treatment for the primary neoplasm and is not part of the eligible treatment regimen
  • Patients requiring 24/7 assistance with activities of daily living (ADLs)
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
  • Uncontrolled intercurrent illness including, but not limited to:

    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia
    • Myocardial infarction ≤ 6 months
    • Wound healing disorder
    • Psychiatric illness/social situations that would limit compliance with study requirements
  • Patients with any severe infection ≤ 4 weeks prior to registration including, but not limited to, hospitalization for complications of infections
  • Patients with an active, known or suspected disease. Patients with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Replacement therapy (e.g., thyroxine, insulin, or physiologic replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment. Patients with vitiligo, Graves' disease, or psoriasis not requiring systemic treatment within the past 30 days are not excluded. Patients with celiac disease controlled with diet modification are not excluded
  • Patients with a condition requiring systemic treatment with either corticosteroids ( > 10 mg daily prednisone equivalent) ≤ 14 days or other medications ≤ 30 days prior to registration. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
  • Concurrent (present during screening) requiring treatment or history of prior malignancy active ≤ 2 years prior to registration (i.e., participants with a history of prior malignancy are eligible if treatment was completed at least 2 years before randomization/treatment assignment and the patient has no evidence of disease). Participants with history of prior early stage basal/squamous cell skin cancer or non-invasive or in situ cancers that have undergone definitive treatment at any time are also eligible
  • Patients have undergone prior solid organ and/or non-autologous hematopoietic stem cell or bone marrow transplant
  • Patients with active or , aside from the exceptions below. Participants with brain metastases are eligible if they are:

    • Asymptomatic
    • Have been treated and participants have neurologically returned to baseline (except for residual signs or symptoms related to the central nervous system [CNS] treatment), and
    • There is no MRI evidence of progression for at least 4 weeks after CNS directed therapy is complete and ≤ 28 days prior to registration
    • In addition, participants must have been either off corticosteroids, or on a stable or decreasing dose of ≤ 10 mg daily prednisone (or equivalent) for at least 2 weeks prior to registration
  • Participants with brain disease treated with whole brain radiation
  • Anticipation of the need for major surgery during the course of study treatment
  • Participants who are pregnant or breastfeeding
  • Treatment with any ≤ 30 days of registration (vaccines that are not live attenuated are allowed, including COVID-19 vaccine)
  • Known human deficiency virus () positive with an AIDS defining opportunistic infection within the last year, or a current \< 350 cells/uL, aside from the exceptions below. Participants with HIV are eligible if:

    • They have received antiviral therapy (ART) for at least 4 weeks prior to treatment assignment as clinically indicated while enrolled in the study
    • They continue on ART as clinically indicated while enrolled on study
    • CD4 counts and viral load are monitored per standard of care by a local healthcare provider
  • History of allergy or to study drug components
  • Any positive test result for virus (HBV) indicating presence of virus (e.g., hepatitis B surface antigen [HBsAg, Australia antigen]) positive
  • Any positive test result for virus (HCV) indicating presence of active viral replication (detectable HCV-ribonucleic acid [RNA]). Note: Participants with positive HCV antibody and an undetectable HCV RNA are eligible to enroll
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Health services research (in-clinic and at-home nivolumab)

    Patients receive nivolumab SC on day 1 of each cycle. Cycles repeat every 28 days in clinic for 2 cycles, then at home by a HHNP for 4 cycles, followed by either in-clinic or at-home administration for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients receive in-home visits by a home health nurse and undergo remote patient monitoring including vital sign measurements and condition-specific symptom assessments throughout the study.

    Other: Home Health Encounter · Biological: Nivolumab · Procedure: Patient Monitoring · Other: Questionnaire Administration

Interventions

  • OtherHome Health Encounter

    Receive in-home visits by a home health nurse

    Also known as: HH, Home, Home Care Visit, Home Health

  • BiologicalNivolumab

    Given SC

    Also known as: ABP 206, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo

  • ProcedurePatient Monitoring

    Undergo remote patient monitoring

    Also known as: medical monitoring, monitor

  • OtherQuestionnaire Administration

    Ancillary studies

07

What researchers measure

Primary outcomes

  1. Change in patient-reported rating of Cancer CARE Cancer Connected Access and Remote Expertise (CARE) after 8 weeks

    Measured using the Consumer Assessment of Healthcare Providers and Systems (CAHPS) Cancer Care Survey assessing "your overall cancer care experience," answered on a scale of 0-10 where 0 is the worst experience possible and 10 is the best experience possible. The change in patient-reported rating of Cancer CARE after 8 weeks of in clinic care to the same rating after 8 weeks of at home care will be compared.

    Time frame: At baseline and up to 24 weeks of in clinic or at home care

Secondary outcomes

  1. Patient preferred treatment location

    The proportion of patients who prefer care at home or express no preference will be computed and compared with the proportion of patients who prefer care in the clinic.

    Time frame: Up to 24 weeks

  2. Patient level of comfort with receiving injections at home

    The proportion of patients who express comfort will be tabulated and a proportion greater than 70% will signify acceptance. Likert patient feedback questions and "Was It Worth It" questions will be described using frequencies and relative frequencies by arm. Numeric analog scale questions will be described using means and standard deviations and compared within patients (if applicable) using paired t-tests. Descriptive estimates at 24 weeks (after 8 weeks of in clinic and 16 weeks of at home care) will be generated throughout.

    Time frame: Up to 24 weeks

  3. Patient-reported symptoms - PRO-CTCAE

    Patient-reported symptoms will be measured using the Patient Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE). In this study, PRO-CTCAE items were chosen based on common symptoms experienced across cancer patients and side effects common with nivolumab. A free-text item will also be included for patients to report other symptoms as willing. Adverse events (AEs) will be tabulated during the 8 weeks in clinic, and during the 8 weeks at home, compared between arms and summarized over the 24 weeks.

    Time frame: Up to 24 weeks

  4. Patient-reported function - EORTC QLQ-F17

    Assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Function 17 (EORTC QLQ-F17), a 17-item patient-reported questionnaire about patient ability to function, overall health and quality of life, and perceived financial impact of cancer and its treatment. The first 15 questions are answered on a scale of 1-4 where 1=not at all, 2=a little, 3=quite a bit, and 4=very much. The final two questions (overall health and overall quality of life during the past week) are answered on a 1-7 numeric analogue scale where 1=very poor and 7=excellent.

    Time frame: Baseline; 8 weeks; 16 weeks; 24 weeks

  5. Patient-reported side effect impact - GP5

    Assessed using the Functional Assessment of Chronic Illness Therapy (FACIT) - Item GP5, "I am bothered by side effects of treatment," which is answered on a scale ranging from 0 (Not at all) to 4 (Very Much). Responses will be computed and compared across patients visits. Mean GP5 scores over time will also be explored.

    Time frame: After 8 weeks of in-clinic and 8 weeks of at home care

  6. Incidence of Adverse Events (AEs)

    The maximum grade for each type of AE will be summarized using Common Terminology Criteria for Adverse Events version 5.0. The frequency and percentage of grade 3+ AEs will be reported and compared using McNemar's test.

    Time frame: At 8 weeks of in-clinic and 8 weeks at home care

  7. Emergency room visits and hospitalizations

    The proportion of patients with an emergency room visit or hospitalization will be computed and compared using McNemar's test. Proportion of patients with emergency room visits or hospitalizations will also be summarized over the entire study.

    Time frame: At 8 weeks of in-clinic and at 8 weeks of at home care

  8. Overall survival (OS)

    OS is defined as the time from study entry to death from any cause. OS will be estimated using the Kaplan-Meier method.

    Time frame: Up to one year post study completion

08

Study locations

1 of 1 sites recruiting
09

References and documents

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for May 2027, 36 months after the start.

Of 153 non-industry phase 2 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 55. This study's planned 36 months is below that.

Counting every sponsor, half of 174 studies reached it within 41 months; a quarter within 28 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Dec 2026 → May 2027 and completion Dec 2026 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2024
First posted
Feb 20, 2024
StartActual
Apr 30, 2024
Primary completionEst.
May 1, 2027was Dec 2026
CompletionEst.
May 1, 2027was Dec 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→May 1, 2027
Oct 2, 2026
Study completion
Dec 31, 2026→May 1, 2027
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Primary completion Dec 31, 2026→May 1, 2027
    Study completion Dec 31, 2026→May 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06265285
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Apr 30, 2024
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Roxana S. Dronca, M.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion